Sign In
Buy NRSN
$0.730
+0.0015 (+0.206%)
At Close: Jul 13, 2026
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
08:45am, Monday, 06'th Jul 2026
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass.
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallma
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
09:20am, Thursday, 25'th Jun 2026
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
09:00am, Monday, 22'nd Jun 2026
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
09:00am, Thursday, 11'th Jun 2026
Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following rece
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
09:00am, Tuesday, 09'th Jun 2026
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Pricing of Insider-Led PIPE Financing
02:30pm, Tuesday, 28'th Apr 2026
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
01:00am, Tuesday, 07'th Apr 2026
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat Ratings
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
09:20am, Monday, 06'th Apr 2026
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PR
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
10:02am, Friday, 03'rd Apr 2026
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirem
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
09:20am, Tuesday, 31'st Mar 2026
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of de
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
09:00am, Tuesday, 24'th Mar 2026
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
08:00am, Wednesday, 18'th Mar 2026
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PR
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower func
